{'52WeekChange': None,
 'SandP52WeekChange': None,
 'address1': '1920 McKinney Avenue',
 'address2': '7th Floor',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 12.65,
 'askSize': 1800,
 'averageDailyVolume10Day': 19825,
 'averageVolume': 82396,
 'averageVolume10days': 19825,
 'beta': None,
 'beta3Year': None,
 'bid': 12.3,
 'bidSize': 800,
 'bookValue': None,
 'category': None,
 'circulatingSupply': None,
 'city': 'Dallas',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 12.79,
 'dayLow': 12.3,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -10.471,
 'enterpriseToRevenue': None,
 'enterpriseValue': 25650612,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 12.87658,
 'fiftyTwoWeekHigh': 15.44,
 'fiftyTwoWeekLow': 11.51,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 1521688,
 'forwardEps': None,
 'forwardPE': None,
 'fromCurrency': None,
 'fullTimeEmployees': 4,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': None,
 'heldPercentInstitutions': None,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/lanternpharma.com',
 'longBusinessSummary': 'Lantern Pharma Inc., a clinical stage oncology '
                        'biotechnology company, focuses on the development of '
                        'precision oncology therapeutics using artificial '
                        'intelligence, genomics, and machine learning. Its '
                        'advanced drug candidate is LP-100, which is in phase '
                        'II clinical trials to treat metastatic, '
                        'castration-resistant, prostate cancer. The company '
                        'also develops LP-300 as a combination therapy for '
                        'female non or never-smokers with non-small cell lung '
                        'cancer adenocarcinoma. In addition, its preclinical '
                        'development drug candidate is LP-184, an alkylating '
                        'agent that damages DNA in cancer cells that '
                        'overexpress certain biomarkers and is from the '
                        'fulvene class of compounds. The company was '
                        'incorporated in 2013 and is based in Dallas, Texas.',
 'longName': 'Lantern Pharma Inc.',
 'market': 'us_market',
 'marketCap': 76600704,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_271124062',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -2451488,
 'nextFiscalYearEnd': 1640908800,
 'open': 12.3,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '972 277 1136',
 'previousClose': 12.65,
 'priceHint': 2,
 'priceToBook': None,
 'priceToSalesTrailing12Months': None,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 12.79,
 'regularMarketDayLow': 12.3,
 'regularMarketOpen': 12.3,
 'regularMarketPreviousClose': 12.65,
 'regularMarketPrice': 12.3,
 'regularMarketVolume': 9063,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 6217590,
 'sharesPercentSharesOut': 0.0005,
 'sharesShort': 26912,
 'sharesShortPreviousMonthDate': None,
 'sharesShortPriorMonth': None,
 'shortName': 'Lantern Pharma Inc.',
 'shortPercentOfFloat': 0.0014,
 'shortRatio': 0.02,
 'startDate': None,
 'state': 'TX',
 'strikePrice': None,
 'symbol': 'LTRN',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': None,
 'twoHundredDayAverage': 12.87658,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': '1e39d5e7-e89b-36b8-9bc7-6149865c08a8',
 'volume': 9063,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.lanternpharma.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '75201'}